Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

AC Immune S.A. (ACIU)

AC Immune S.A. (ACIU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

AC Immune S.A. EPFL INNOVATION PARK BUILDING B LAUSANNE V8 1015 CHE

www.acimmune.com Employees: 161 P: 41-21-345-9121 F: +41 213459120

Description:

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.

Key Statistics

Overview:

Market Capitalization, $K 290,884
Enterprise Value, $K 203,454
Shares Outstanding, K 98,940
Annual Sales, $ 16,490 K
Annual Net Income, $ -60,410 K
Last Quarter Sales, $ 760 K
Last Quarter Net Income, $ -25,170 K
EBIT, $ -84,380 K
EBITDA, $ -81,910 K
60-Month Beta 1.28
% of Insider Shareholders 4.60%
% of Institutional Shareholders 51.36%
Float, K 94,389
% Float 95.40%
Short Volume Ratio 0.52

Growth:

1-Year Return 19.12%
3-Year Return -50.17%
5-Year Return -57.76%
5-Year Revenue Growth 124.05%
5-Year Earnings Growth 13.41%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.25 on 08/06/24
Next Earnings Date 11/08/24 [--]
Earnings Per Share ttm -0.72
EPS Growth vs. Prev Qtr -19.05%
EPS Growth vs. Prev Year -13.64%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ACIU Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -43.72%
Return-on-Assets % -33.24%
Profit Margin % -366.34%
Debt/Equity 0.00
Price/Sales 18.01
Price/Cash Flow N/A
Price/Book 2.17
Book Value/Share 1.38
Interest Coverage -301.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar